Anticancer Activity of Pinostilbene in Prostate Cancer
Faculty Mentor
Avinash Kumar
Major/Area of Research
Cancer Pharmacology
Description
INTRODUCTION: Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths among men in the U.S. Although current therapies involving androgen receptor pathway inhibitors have improved survival rates, treatment resistance is commonly observed. Therefore, new therapeutic approaches should continue to be investigated. The anticancer activity of resveratrol and its derivatives has been widely demonstrated. However, pinostilbene, a monomethylated resveratrol derivative, is less well studied, and reports on pinostilbene’s anticancer activity in prostate cancer are limited. This study aims to investigate the anticancer activity of pinostilbene on androgen receptor-positive and androgen receptornegative prostate cancer cell lines.
METHOD: We performed cell viability assay on PC3, PC3M, DU145, LNCaP, C4, C4-2, C4-2b, and 22Rv1 cell lines to evaluate pinostilbene’s cytotoxic effects. We found that pinostilbene’s IC50 values for the above cell lines were 14.91, 6.43, 3.6, 22.42, 4.30, 5.74, 4.52, and 26.35 μM, respectively.
CONCLUSION: Our data shows that pinostilbene inhibited the viability of all prostate cancer cell lines tested. However, its anticancer activity is more potent in androgen receptor-negative and more invasive cell lines compared to androgen receptor-positive and their less invasive counterparts.
Anticancer Activity of Pinostilbene in Prostate Cancer
INTRODUCTION: Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths among men in the U.S. Although current therapies involving androgen receptor pathway inhibitors have improved survival rates, treatment resistance is commonly observed. Therefore, new therapeutic approaches should continue to be investigated. The anticancer activity of resveratrol and its derivatives has been widely demonstrated. However, pinostilbene, a monomethylated resveratrol derivative, is less well studied, and reports on pinostilbene’s anticancer activity in prostate cancer are limited. This study aims to investigate the anticancer activity of pinostilbene on androgen receptor-positive and androgen receptornegative prostate cancer cell lines.
METHOD: We performed cell viability assay on PC3, PC3M, DU145, LNCaP, C4, C4-2, C4-2b, and 22Rv1 cell lines to evaluate pinostilbene’s cytotoxic effects. We found that pinostilbene’s IC50 values for the above cell lines were 14.91, 6.43, 3.6, 22.42, 4.30, 5.74, 4.52, and 26.35 μM, respectively.
CONCLUSION: Our data shows that pinostilbene inhibited the viability of all prostate cancer cell lines tested. However, its anticancer activity is more potent in androgen receptor-negative and more invasive cell lines compared to androgen receptor-positive and their less invasive counterparts.